Dublin, May 13, 2019 (GLOBE NEWSWIRE) -- The "Global Staphylococcal Infection Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The staphylococcal infection drugs market will register a CAGR of nearly 3% by 2023.
Regulatory agencies are granting special drugs designations for the development of drugs for the treatment of infectious diseases, including those used for the treatment of staphylococcal infection. Special drug designations offer incentives for the development of new drugs for the treatment which is encouraging more and more manufacturers to invest in the development of drugs, which in turn is driving the market.
Increasing incidence of staphylococcal infections
The emergence of antibiotics resistant strains has led to increased incidence of staphylococcal infections. Skin and soft tissue infections are the most common type of infections caused by staphylococcal. Thus, rising incidence of staphylococcal infections is a major driver contributing to the market growth.
Lack of vaccines and new drug classes
Unlike most of the infectious diseases that can be prevented by vaccines, there is no approved vaccine for the prevention of staphylococcal infections. The rapid evolution of the bacteria responsible along with the following factors pose a major hurdle to the development of vaccines against staphylococcal infections.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Merck & Co. Inc. and Pfizer Inc the competitive environment is quite intense. Factors such as the increasing incidence of staphylococcal infections and special drug designations, will provide considerable growth opportunities to staphylococcal infection drugs manufactures.
Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., and Pfizer Inc. are some of the major companies covered in this report.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Beta-lactams - Market size and forecast 2018-2023
- Peptides - Market size and forecast 2018-2023
- Quinolones - Market size and forecast 2018-2023
- Macrolides - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Allergan Plc
- Bayer AG
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Pfizer Inc.
PART 14: APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/ozovum
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.